Biotech trial pipeline
registry pull 2026-08-19Every registered study we hold for listed drug and biotech companies — running, finished or stopped. Phases, statuses, enrollment and the three date axes are the values the sponsor filed with ClinicalTrials.gov. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Most recently updated records
filter, search and page through →32,500 studies match. Showing the first 100 of 32,500 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HUMA | Humacyte, Inc. | $162M | Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for HemodialysisNCT02644941results2025-03-30Number of Participants With Loss of Secondary Patency | Phase 3 | Completed | Biological: Human Acellular Vessel (HAV) · Device: ePTFE graft | Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access | 355 | 2016-05-24 | May 2019actual | — | 2026-08-19 |
| ABBV | AbbVie | $457.5B | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCT02966756Overall Response Rate (ORR) | Phase 2 | Active, not recruiting | Drug: Venetoclax | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 66 | 2017-10-12 | Dec 2030 | ≤ 1,595 d | 2026-08-19 |
| PFE | Pfizer | $155.3B | Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A AdultsNCT04370054results2025-08-17Total Annualized Bleeding Rate (ABR) | Phase 3 | Active, not recruiting | Biological: PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy | Hemophilia A | 77 | 2020-08-18 | 2024-06-17actual | — | 2026-08-19 |
| EW | Edwards Lifesciences | $52.4B | Beating Heart Mitral Valve Repair With the HARPOON™ SystemNCT04375332Change in NYHA classification from Baseline to 5 years | Not applicable | Active, not recruiting | Device: HARPOON™ Beating Heart Mitral Valve Repair System | Mitral Regurgitation | 25 | 2020-12-16 | 2027-12-20 | in 488 d | 2026-08-19 |
| EW | Edwards Lifesciences | $52.4B | MiCLASP Post Market Clinical Follow-Up (PMCF) StudyNCT04430075observationalNumber of patients with major adverse events (MAE rates) | — | Active, not recruiting | Device: Edwards PASCAL Transcatheter Valve Repair System and Edwards PASCAL Precision Transcatheter Valve Repair System | Mitral Regurgitation, Mitral Insufficiency | 1,000 | 2019-08-23 | 2025-09-04actual | — | 2026-08-19 |
| ABBV | AbbVie | $457.5B | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)NCT04567550Part 1: Proportion of participants achieving a 2-step or greater improvement in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography at Week 48 | Phase 2 | Active, not recruiting | Genetic: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, ABBV-RGX-314 Dose 4 · Drug: Topical Steroid · Biological: Aflibercept | Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME) | 139 | 2020-11-20 | 2026-06-18actual | — | 2026-08-19 |
| RGNX | REGENXBIO Inc. | $731M | Long-term Follow-Up for RGX-121NCT04597385observationalLong-term Safety of RGX-121 | — | Active, not recruiting | Other: Long-term Follow-Up | Mucopolysaccharidosis II | 27 | 2021-03-14 | Oct 2028 | ≤ 804 d | 2026-08-19 |
| PLYX | Polaryx Therapeutics, Inc. | $105M | Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3NCT04637282Efficacy of PLX-200 in CLN3 as assessed by the change in the motor score of the Hamburg Rating Scale compared with that of the Placebo group | Phase 3 | Withdrawnsponsor's stated reason: Study has yet to begin and removing to avoid further participant outreach to sponsor | Drug: PLX-200, Placebo | Juvenile Neuronal Ceroid Lipofuscinosis | 0 | 2026-11-01 | 2026-12-31 | in 134 d | 2026-08-19 |
| AZN | AstraZeneca | — | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesNCT04644068The number of subjects with adverse events/serious adverse events | Phase 1/2 | Active, not recruiting | Drug: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant | Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 | 702 | 2020-11-12 | 2027-05-28 | in 282 d | 2026-08-19 |
| BSX | Boston Scientific Corporation | $73.1B | Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral VasculatureNCT04674969observationalMajor Adverse Events | — | Recruiting | Device: Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device. | Peripheral Vascular Diseases | 5,000 | 2021-03-29 | Jan 2028 | ≤ 530 d | 2026-08-19 |
| AZN | AstraZeneca | — | Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid TumoursNCT04999969results2025-11-26Number of Participants With Adverse Events (AEs), Immune Mediated AEs (imAEs) and Serious AEs (SAEs) | Phase 2 | Active, not recruiting | Drug: AZD0171, Durvalumab, Gemcitabine, Nab-paclitaxel | Locally Advanced or Metastatic Solid Tumours | 126 | 2021-12-10 | 2024-10-07actual | — | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNCT05006716Phase 1: Number of Participants with Adverse Events (AEs) | Phase 1/2 | Recruiting | Drug: BGB-16673 | B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma | 645 | 2021-09-13 | Nov 2026 | ≤ 103 d | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaNCT05100862Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC) | Phase 3 | Active, not recruiting | Drug: Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab | Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma | 799 | 2022-03-10 | Jul 2028 | ≤ 712 d | 2026-08-19 |
| 4568.T | Daiichi Sankyo | $31.6B | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsNCT05215340Progression-free Survival Based on Blinded Independent Central Review in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With Pembrolizumab | Phase 3 | Active, not recruiting | Drug: Datopotamab Deruxtecan, Pembrolizumab | Metastatic Non Small Cell Lung Cancer | 740 | 2022-03-04 | 2030-03-04 | in 1,293 d | 2026-08-19 |
| VIR | Vir Biotechnology, Inc. | $1.6B | To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing CancersNCT05356741Incidence of dose-limiting toxicity - Part 1 and Part 2 | Phase 1/2 | Recruiting | Drug: VIR-5818, pembrolizumab | Locally Advanced or Metastatic HER2-Expressing Cancers | 645 | 2022-04-13 | Apr 2028 | ≤ 620 d | 2026-08-19 |
| EBS | Emergent BioSolutions | $239M | Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy AdultsNCT05377255Mean naloxone plasma concentration AP003 dosing periods. | Phase 1 | Completed | Combination product: 16 mg naloxone AP003, 8 mg naloxone NARCAN Nasal Spray | Opioid Overdose | 24 | 2022-03-28 | 2022-05-10actual | — | 2026-08-19 |
| BMY | Bristol-Myers Squibb | $134.9B | A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)NCT05489705observationalIncidence rate of new or worsening heart failure due to systolic dysfunction among participants with symptomatic obstructive HCM during periods of exposure to mavacamten and other oHCM treatment | — | Recruiting | Drug: Mavacamten, Non-mavacamten symptomatic oHCM therapy | Obstructive Hypertrophic Cardiomyopathy | 1,700 | 2022-08-16 | 2029-08-17 | in 1,094 d | 2026-08-19 |
| BSX | Boston Scientific Corporation | $73.1B | Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation SystemNCT05501873observationalPrimary Effectiveness Endpoint | — | Active, not recruiting | Device: FARAPULSE Pulsed Field Ablation system | Atrial Fibrillation | 1,173 | 2023-03-24 | 2025-10-21actual | — | 2026-08-19 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.NCT05568706results2026-08-19Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms | Phase 2 | Completed | Drug: EDP-938, Placebo | RSV Infection | 187 | 2022-11-29 | 2025-06-23actual | — | 2026-08-19 |
| AZN | AstraZeneca | — | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951Invasive breast cancer-free survival (IBCFS) | Phase 3 | Recruiting | Drug: Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane | Breast Cancer, Early Breast Cancer | 4,300 | 2023-03-31 | 2027-04-20 | in 244 d | 2026-08-19 |
| CRNX | Crinetics Pharmaceuticals Inc. | $9.0B | A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's SyndromeNCT05804669Proportion of participants with treatment emergent adverse events (TEAEs) | Phase 1/2 | Active, not recruiting | Drug: atumelnant | Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome | 19 | 2023-10-12 | Oct 2026 | ≤ 73 d | 2026-08-19 |
| BOLD | Boundless Bio, Inc. | $65M | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsNCT05827614Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825 | Phase 1 | Terminatedsponsor's stated reason: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal. | Drug: BBI-355, Erlotinib, Futibatinib, BBI-825 | Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer | 85 | 2023-03-24 | 2026-03-17actual | — | 2026-08-19 |
| COCP | Cocrystal Pharma, Inc. | $21M | CDI-988 Safety Study in Healthy ParticipantsNCT05977140results2026-08-19Adverse Events | Phase 1 | Completed | Drug: CDI-988, Placebo | Healthy Volunteers | 94 | 2023-09-27 | 2025-05-23actual | — | 2026-08-19 |
| AZN | AstraZeneca | — | A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular CarcinomaNCT060848841. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phase | Phase 1/2 | Active, not recruiting | Biological: AZD5851 | Hepatocellular Carcinoma | 94 | 2023-12-14 | 2027-12-13 | in 481 d | 2026-08-19 |
| AZN | AstraZeneca | — | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)NCT06087835Change in eGFR from baseline | Phase 3 | Active, not recruiting | Drug: Zibotentan/Dapagliflozin, Dapagliflozin | Chronic Kidney Disease With High Proteinuria | 1,835 | 2023-11-07 | 2027-02-18 | in 183 d | 2026-08-19 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsNCT06101134results2026-04-09Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose | Phase 2 | Active, not recruiting | Drug: relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab, nivolumab+rHuPH20 | Melanoma | 100 | 2023-11-06 | 2025-04-10actual | — | 2026-08-19 |
| AZN | AstraZeneca | — | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple MyelomaNCT06106945Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only) | Phase 1/2 | Recruiting | Drug: AZD0305, Elranatamab, Pomalidomide, Dexamethasone | Multiple Myeloma | 226 | 2023-12-05 | 2027-08-16 | in 362 d | 2026-08-19 |
| AZN | AstraZeneca | — | Chronic Kidney Disease Registry Platform StudyNCT06117852observationalDisease Progression in CKD Patients | — | Active, not recruiting | — | Chronic Kidney Diseases | 5,000 | 2023-11-28 | 2028-11-30 | in 834 d | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent | Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer | 399 | 2023-12-01 | Nov 2028 | ≤ 834 d | 2026-08-19 |
| AZN | AstraZeneca | — | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaNCT06137118Part A: Frequency of DLTs | Phase 1/2 | Recruiting | Drug: Surovatamig | B-cell Acute Lymphoblastic Leukemia (B-ALL) | 255 | 2023-12-29 | 2028-02-11 | in 541 d | 2026-08-19 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717NCT06153966Incidence of treatment-emergent adverse events. | Phase 1/2 | Active, not recruiting | Drug: ION717, Placebo | Prion Disease | 85 | 2024-01-04 | Feb 2027 | ≤ 193 d | 2026-08-19 |
| AZN | AstraZeneca | — | To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsNCT06194448PFS (Progression-Free Survival) | Phase 2 | Active, not recruiting | Drug: Osimertinib, Cisplatin or Carboplatin; Pemetrexed or Paclitaxel, Radiation | Lung Cancer | 76 | 2024-04-21 | 2026-07-07actual | — | 2026-08-19 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)NCT06246916Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on blinded independent central review (BICR) | Phase 3 | Recruiting | Drug: fianlimab, cemiplimab, relatlimab+nivolumab | Melanoma | 560 | 2024-09-09 | 2027-03-22 | in 215 d | 2026-08-19 |
| AZN | AstraZeneca | — | Non-interventional Study of Patients With Transthyretin (ATTR) AmyloidosisNCT06465810observationalDemographic characteristics (overall and in patients initiating a treatment with eplontersen) | — | Recruiting | Drug: Treatment of transthyretin (ATTR) amyloidosis in observational study setting | Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR | 1,850 | 2024-06-25 | 2031-12-29 | in 1,958 d | 2026-08-19 |
| AZN | AstraZeneca | — | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerNCT06467357Safety Run In: To evaluate the safety and tolerability of T-DXd with rilvegostomig | Phase 3 | Recruiting | Drug: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig | Biliary Tract Cancer | 620 | 2024-08-12 | 2028-06-12 | in 663 d | 2026-08-19 |
| AZN | AstraZeneca | — | A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsNCT06549595SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEs | Phase 3 | Recruiting | Drug: Surovatamig, R-CHOP, R-CVP, BR | Untreated Follicular Lymphoma | 1,018 | 2024-08-07 | 2031-11-26 | in 1,925 d | 2026-08-19 |
| ARDX | Ardelyx | $977M | 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 YrsNCT06553547Average weekly SBM (week 4) | Phase 2 | Completed | Drug: Tenapanor, Placebo | Irritable Bowel Syndrome With Constipation (IBS-C) | 72 | 2024-07-24 | 2026-07-07actual | — | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesNCT06634589Substudy 1 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse events | Phase 1/2 | Recruiting | Drug: BGB-16673, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab | B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma | 80 | 2024-11-27 | 2028-12-02 | in 836 d | 2026-08-19 |
| BJDX | Bluejay Diagnostics, Inc. | $4M | Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation StudyNCT06654895observational28-day all-cause mortality [Time Frame: within 28 days after inclusion] participants will be followed up for 28 days | — | Active, not recruiting | — | Sepsis, Septic Shock | 700 | 2024-11-12 | 2026-09-30 | in 42 d | 2026-08-19 |
| BNTX | BioNTech SE | — | A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy PeopleNCT06683352results2026-08-19Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination | Phase 1/2 | Completed | Biological: Investigational Influenza Vaccine, COVID-19 Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2 · Combination product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo | Influenza,Human, COVID-19 | 1,353 | 2024-11-11 | 2025-07-15actual | — | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)NCT06742996Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC) | Phase 3 | Recruiting | Drug: Sonrotoclax, Zanubrutinib, Placebo | Mantle Cell Lymphoma, B Cell Lymphoma | 300 | 2025-03-05 | 2028-08-31 | in 743 d | 2026-08-19 |
| SMMT | Summit Therapeutics | $10.2B | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514Overall Survival (OS) | Phase 3 | Recruiting | Biological: Ivonescimab Injection, Pembrolizumab Injection | Non-Small Cell Lung Cancer | 780 | 2025-02-27 | Apr 2028 | ≤ 620 d | 2026-08-19 |
| SOBI.ST | Swedish Orphan Biovitrum | — | A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)NCT06782373Overall Clinical Response (OCR), defined as achieving Clinical Response or better at any time during the double-blind treatment period. | Phase 2 | Active, not recruiting | Drug: Pacritinib, Placebo | VEXAS, VEXAS Syndrome | 78 | 2025-05-28 | 2026-12-30 | in 133 d | 2026-08-19 |
| INCY | Incyte Corporation | $24.7B | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic DermatitisNCT06832618VC Period: Binary response status of Eczema Area and Severity Index 75 (EASI75) | Phase 3 | Active, not recruiting | Drug: Ruxolitinib, Vehicle Cream | Atopic Dermatitis | 159 | 2025-06-17 | 2026-08-07actual | — | 2026-08-19 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisNCT06869551Time to first flare during the withdrawal period | Phase 3 | Recruiting | Drug: Deucravacitinib · Other: Placebo | Juvenile Psoriatic Arthritis | 60 | 2025-03-13 | 2030-03-06 | in 1,295 d | 2026-08-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver FunctionNCT06916078Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Lepodisiran | Phase 1 | Completed | Drug: Lepodisiran | Liver Dysfunction, Healthy | 30 | 2025-04-23 | 2026-07-13actual | — | 2026-08-19 |
| BIIB | Biogen | $31.4B | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)NCT06935357Percent Change From Baseline in Proteinuria as Measured by the Urine Protein: Creatinine Ratio (UPCR) | Phase 3 | Recruiting | Drug: Felzartamab, Placebo | Immunoglobulin A Nephropathy (IgAN) | 454 | 2025-05-08 | 2027-05-31 | in 285 d | 2026-08-19 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)NCT06937229Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Recruiting | Drug: KarXT, KarX-EC | Alzheimer Disease, Agitation | 650 | 2025-12-02 | 2029-06-22 | in 1,038 d | 2026-08-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 DiabetesNCT06945419Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Completed | Drug: LY4086940, Placebo, LY4086940 | Healthy, Overweight, Obesity, Type 2 Diabetes | 219 | 2025-04-23 | 2026-08-05actual | — | 2026-08-19 |
| BIIB | Biogen | $31.4B | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)NCT06962800Percentage of Participants who Achieve Complete Remission (CR) at Week 104 | Phase 3 | Recruiting | Drug: Felzartamab, Tacrolimus, Standard of Care IST | Primary Membranous Nephropathy | 180 | 2025-05-22 | 2030-01-28 | in 1,258 d | 2026-08-19 |
| AMGN | Amgen | $229.9B | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)NCT06987539Maximum Observed Concentration (Cmax) of Inebilizumab | Phase 2 | Recruiting | Drug: Inebilizumab | Generalized Myasthenia Gravis | 15 | 2026-07-21 | 2030-03-13 | in 1,302 d | 2026-08-19 |
| BSX | Boston Scientific Corporation | $73.1B | Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric BypassNCT07015424Total Body Weight Loss | Not applicable | Recruiting | Device: TORe with OverStitch · Behavioral: Intensive lifestyle modification | Weight Regain, Weight Loss | 108 | 2026-04-14 | Nov 2026 | ≤ 103 d | 2026-08-19 |
| ARVN | Arvinas Inc. | $605M | A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationNCT07023731Part A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806 | Phase 1/2 | Active, not recruiting | Drug: ARV-806 | KRAS G12D Mutation, Advanced Solid Cancer | 159 | 2025-05-29 | 2026-11-30 | in 103 d | 2026-08-19 |
| SNY | Sanofi | — | Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)NCT07038473Proportion of at-risk (first-degree) relatives of T1D probands who meet the diagnostic criteria for Stage 1 or Stage 2 T1D | Not applicable | Recruiting | Procedure: Investigational Procedure | Type 1 Diabetes | 3,500 | 2025-12-17 | 2026-12-25 | in 128 d | 2026-08-19 |
| AZN | AstraZeneca | — | Anifrolumab Pregnancy StudyNCT07049653observationalRisk of major congenital malformations (MCM) | — | Recruiting | — | Systemic Lupus Erythematosus | 500 | 2026-06-04 | 2030-12-10 | in 1,574 d | 2026-08-19 |
| BMY | Bristol-Myers Squibb | $134.9B | Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)NCT07101094observationalParticipant medication preference as assessed by the Preference of Medication (POM) questionnaire | — | Recruiting | Drug: xanomeline and trospium chloride (X/T) therapy | Schizophrenia | 300 | 2025-09-22 | 2029-01-31 | in 896 d | 2026-08-19 |
| AZN | AstraZeneca | — | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion) | Phase 1/2 | Recruiting | Drug: AZD6750, rilvegostomig | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma | 120 | 2025-07-29 | 2029-10-02 | in 1,140 d | 2026-08-19 |
| GILD | Gilead Sciences | $177.9B | Study of GS-5319 Given Alone or in Combination in Adults With Solid TumorsNCT07128303Percentage of Participants With Adverse Events (AEs) and Serous Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: GS-5319, Carboplatin, Pemetrexed, Pembrolizumab | Advanced Solid Tumor | 476 | 2025-08-28 | May 2028 | ≤ 651 d | 2026-08-19 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109Time to First Occurrence of a Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Heart Failure (HF) Event (Hospitalization for HF or Urgent HF Visit) | Phase 3 | Recruiting | Drug: Zilebesiran, Placebo | High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk | 11,000 | 2025-09-22 | 2030-09-30 | in 1,503 d | 2026-08-19 |
| IRON | Disc Medicine, Inc | $3.1B | A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)NCT07187973Safety and tolerability of DISC-3405 administration in participants with SCD | Phase 1 | Recruiting | Drug: DISC-3405 | Sickle Cell Disease | 24 | 2026-01-06 | Jun 2027 | ≤ 315 d | 2026-08-19 |
| NVO | Novo Nordisk A/S | — | CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811Composite Outcome of cardiovascular (CV) deaths and recurrent CV events (CV hospitalisations and urgent heart failure [HF] visits) | Phase 3 | Recruiting | Drug: NNC6019-0001, Placebo (NNC6019-0001) | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | 1,280 | 2025-10-02 | 2029-06-29 | in 1,045 d | 2026-08-19 |
| REGN | Regeneron Pharmaceuticals | $76.1B | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsNCT07213778Incidence of the composite endpoint of symptomatic VTE and all-cause death | Phase 3 | Recruiting | Drug: REGN7508, Acetylsalicylic Acid (ASA), Placebo | Symptomatic Venous Thromboembolism (VTE) | 2,000 | 2025-11-24 | 2027-05-17 | in 271 d | 2026-08-19 |
| BMY | Bristol-Myers Squibb | $134.9B | A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle EastNCT07215975observationalChange in transfusion burden | — | Recruiting | Drug: Luspatercept | β-thalassemia | 200 | 2026-06-26 | 2030-02-28 | in 1,289 d | 2026-08-19 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)NCT07221500Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC) | Phase 2 | Recruiting | Drug: NX-5948 | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 100 | 2025-10-15 | Jan 2028 | ≤ 530 d | 2026-08-19 |
| ASND | Ascendis Pharma A/S | — | Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient DisordersNCT07221851Annualized Height Velocity (AHV) (cm/year) | Phase 3 | Recruiting | Combination product: Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector | Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery | 186 | 2025-12-12 | Feb 2028 | ≤ 559 d | 2026-08-19 |
| VNDA | Vanda Pharmaceuticals | $329M | Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual PatientNCT07223632Assessment of safety of therapy with VCA-894A when administered via intrathecal injection, as measured by the incidence of adverse events. | Phase 1/2 | Active, not recruiting | Drug: VCA-894A | Charcot Marie Tooth Disease (CMT), Neuromuscular Diseases (NMD) | 1 | 2025-05-13 | Mar 2027 | ≤ 224 d | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid TumorsNCT07226349Phase 1a: Number of Participants with Adverse Events (AEs) | Phase 1 | Recruiting | Drug: BG-75098, BGB-43395, Fulvestrant | Advanced Solid Tumor | 105 | 2025-12-11 | 2028-11-01 | in 805 d | 2026-08-19 |
| CVRX | CVRx, Inc. | $73M | Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart FailureNCT07232030Primary Effectiveness Endpoint | Not applicable | Recruiting | Device: Barostim System · Other: Usual care medical management | Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III | 2,500 | 2026-04-24 | Jan 2033 | ≤ 2,357 d | 2026-08-19 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous TumorsNCT07241039Number of Participants with Adverse Events (AE)s | Phase 1 | Recruiting | Drug: ABBV-711, Budigalimab | Advanced Squamous Tumors | 220 | 2025-11-20 | Apr 2029 | ≤ 985 d | 2026-08-19 |
| CORT | Corcept Therapeutics | $12.8B | Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesNCT07276373Number of Patients With 1 or More Adverse Event | Phase 1/2 | Recruiting | Drug: Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg, Nivolumab | Neoplasms | 50 | 2026-01-16 | Sep 2026 | ≤ 42 d | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaNCT07277231Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC) | Phase 3 | Recruiting | Drug: Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax | Chronic Lymphocytic Leukemia | 500 | 2026-01-22 | Feb 2031 | ≤ 1,654 d | 2026-08-19 |
| CTNM | Contineum Therapeutics | $335M | Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisNCT07284459Absolute change in forced vital capacity (FVC) (mL) | Phase 2 | Recruiting | Drug: PIPE-791 Dose A, PIPE-791 Dose B, Placebo | Idiopathic Pulmonary Fibrosis | 324 | 2026-01-08 | May 2028 | ≤ 651 d | 2026-08-19 |
| TENX | Tenax Therapeutics, Inc. | $64M | LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2NCT072883986-Minute Walk Distance (6MWD) | Phase 3 | Recruiting | Drug: TNX-103, Placebo | Pulmonary Hypertension Associated With HFpEF | 540 | 2026-03-03 | 2028-06-30 | in 681 d | 2026-08-19 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)NCT07318597Change from baseline in Pulmonary Vascular Resistance (PVR) | Phase 2 | Recruiting | Drug: REGN13335, Placebo | Pulmonary Arterial Hypertension (PAH) | 99 | 2026-05-06 | 2028-02-27 | in 557 d | 2026-08-19 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery DiseaseNCT07318610Time-to-first occurrence of a major thrombotic vascular event, consisting of Acute Limb Ischemia (ALI), major amputation (above the ankle) of vascular etiology, Myocardial Infarction (MI), ischemic stroke, or Cardiovascular (CV) death | Phase 3 | Recruiting | Drug: REGN7508, REGN9933, Placebo, Rivaroxaban | Peripheral Artery Disease (PAD) | 7,050 | 2026-07-10 | 2029-08-18 | in 1,095 d | 2026-08-19 |
| AURA | Aura Biosciences | $846M | A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal MelanomaNCT07338968observationalIncidence of adverse events (AEs)/serious AEs. | — | Enrolling by invitation | Other: Observational | Choroidal Melanoma, Indeterminate Lesions | 100 | 2026-03-27 | 2033-08-15 | in 2,553 d | 2026-08-19 |
| BSX | Boston Scientific Corporation | $73.1B | A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation ProcedureNCT07353710The incidence of procedure related serious adverse events and all adverse events | Not applicable | Recruiting | Device: ICE Image Acquisition | Atrial Arrhythmia, Intracardiac Echocardiography | 200 | 2026-07-28 | 2027-06-30 | in 315 d | 2026-08-19 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerNCT07365241Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR) | Phase 3 | Recruiting | Drug: ABBV-706, Topotecan, Topotecan, Lurbinectedin, Amrubicin | Small Cell Lung Cancer | 531 | 2026-07-02 | Sep 2030 | ≤ 1,503 d | 2026-08-19 |
| EIKN | Eikon Therapeutics | $567M | A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.NCT07365319Progression-free survival (PFS) | Phase 2/3 | Recruiting | Drug: EIK1001, Pembrolizumab (KEYTRUDA®), Placebo, Paclitaxel + Carboplatin, Nab-paclitaxel + Carboplatin, Pemetrexed + Cisplatin /Carboplatin | Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC | 750 | 2026-06-15 | 2035-12-31 | in 3,421 d | 2026-08-19 |
| BMY | Bristol-Myers Squibb | $134.9B | Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)NCT07379827observationalTreatment titration and switch regimens as described by the prescribing clinician | — | Recruiting | Drug: Xanomeline and trospium chloride (KarXT) | Schizophrenia | 1,500 | 2026-02-26 | 2028-06-20 | in 671 d | 2026-08-19 |
| BOLD | Boundless Bio, Inc. | $65M | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast CancerNCT07408089Rate of dose limiting toxicities (DLTs) in each BBI-940 monotherapy dose escalation cohort. | Phase 1 | Terminatedsponsor's stated reason: The study was terminated primarily due to a business decision related to a corporate transaction and was not driven by any safety signal. | Drug: BBI-940, Fulvestrant | Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer | 8 | 2026-02-25 | 2026-07-28actual | — | 2026-08-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionNCT07426380Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136 | Phase 1 | Active, not recruiting | Drug: LY3841136 | Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic, Renal Impairment, Renal Insufficiency, End Stage Kidney Disease | 28 | 2026-02-24 | Oct 2026 | ≤ 73 d | 2026-08-19 |
| AZN | AstraZeneca | — | Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued TreatmentNCT07444567Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumab | Phase 3 | Recruiting | Drug: Benralizumab | Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES) | 230 | 2026-07-24 | 2030-01-03 | in 1,233 d | 2026-08-19 |
| ONCY | Oncolytics Biotech | $108M | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal CancerNCT07446322Overall Response Rate (ORR) | Phase 2 | Recruiting | Drug: Bevacizumab, FOLFIRI, Pelareorep | Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer | 60 | 2026-04-30 | 2027-08-30 | in 376 d | 2026-08-19 |
| GILD | Gilead Sciences | $177.9B | Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV PreventionNCT07473778observationalProportion of Participants with LEN PrEP Persistence at Week 52 | — | Recruiting | Drug: Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet | HIV Infections | 3,000 | 2026-03-17 | Apr 2028 | ≤ 620 d | 2026-08-19 |
| TSHA | Taysha Gene Therapies, Inc. | $2.0B | Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett SyndromeNCT07480564Primary Safety | Phase 3 | Active, not recruiting | Genetic: TSHA-102 | Rett Syndrome | 4 | 2026-05-08 | Jun 2031 | ≤ 1,776 d | 2026-08-19 |
| INSM | Insmed Incorporated | $28.1B | A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)NCT07481981Change in 6-Minute Walk Distance (6MWD) Measured at 1 to 3 Hours Post-Dose From Baseline at Week 24 | Phase 3 | Recruiting | Drug: Treprostinil Palmitil Inhalation Powder, Placebo | Pulmonary Arterial Hypertension | 344 | 2026-07-21 | 2028-12-28 | in 862 d | 2026-08-19 |
| RMD | ResMed | $31.7B | Exploration of Current and New Technologies for Accuracy of Diagnosing OSANCT07485582observationalSensitivity | — | Not yet recruiting | Device: Device A, Device B, Device C, Device D, Device E · Diagnostic test: Screener A | Obstructive Sleep Apnea | 90 | Sep 2026 | Oct 2026 | ≤ 73 d | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641Progression-Free Survival (PFS) Determined by Blinded Independent Central Review (BICR) | Phase 3 | Recruiting | Drug: BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib | HR+/HER2- Breast Cancer | 1,056 | 2026-05-22 | Apr 2029 | ≤ 985 d | 2026-08-19 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersNCT07493304Occurrence of Treatment-Emergent Adverse Events (TEAEs) | Phase 3 | Recruiting | Drug: REGN7508, Apixaban | Venous Thromboembolism (VTE) | 1,600 | 2026-08-31 | 2031-07-08 | in 1,784 d | 2026-08-19 |
| IBRX | ImmunityBio, Inc. | $8.2B | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic LeukemiaNCT07556757Evaluate safety of CD19 t-haNK as a single agent in participants with selected CD19+ relapsed B-ALL. | Phase 1 | Terminatedsponsor's stated reason: Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug | Drug: CD19 t-haNK | B-ALL, Leukemia | 4 | 2025-04-11 | 2026-07-01actual | — | 2026-08-19 |
| CRNX | Crinetics Pharmaceuticals Inc. | $9.0B | Drug-Drug Interaction Study of Atumelnant in Healthy ParticipantsNCT07570082Cohort 1: Pharmacokinetics (AUC 0-last) | Phase 1 | Completed | Drug: Atumelnant, Carbamazepine, Midazolam, Digoxin, Metformin | Healthy Volunteers | 46 | 2026-05-28 | 2026-06-30actual | — | 2026-08-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4065967 in Healthy ParticipantsNCT07607483Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4065967 | Phase 1 | Completed | Drug: LY4065967 Tablet, LY4065967 Formulated Capsule, LY4065967 Capsule | Healthy | 36 | 2026-06-03 | 2026-07-27actual | — | 2026-08-19 |
| 4519.T | Chugai Pharmaceutical | $72.2B | AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerNCT07617337Adverse events [PartA,B] | Phase 1 | Recruiting | Drug: AQUA07, Lorlatinib | ALK Positive Non-small Cell Lung Cancer | 102 | 2026-07-24 | 2030-08-31 | in 1,473 d | 2026-08-19 |
| FBRX | Forte Biosciences, Inc. | $1.6B | A Study Testing the Safety and Effects of FB102 in Healthy VolunteersNCT07623057Incidence, severity, and relationship to treatment of treatment-emergent adverse events (TEAEs) | Phase 1 | Recruiting | Drug: FB102 Single dose, FB102 Multiple doses, FB102 Placebo | Healthy Volunteer | 48 | 2026-06-23 | Feb 2027 | ≤ 193 d | 2026-08-19 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IHNCT07625280Change in Epworth Sleepiness Scale (ESS) scores | Phase 3 | Recruiting | Drug: Xywav · Other: Placebo | Narcolepsy, Idiopathic Hypersomnia | 120 | 2026-07-09 | 2027-12-23 | in 491 d | 2026-08-19 |
| LLY | Eli Lilly and Company | $1.15T | A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back PainNCT07641504Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) | Phase 2 | Recruiting | Drug: LY4065967, Placebo | Chronic Pain, Low Back Pain | 150 | 2026-08-12 | Apr 2027 | ≤ 254 d | 2026-08-19 |
| LLY | Eli Lilly and Company | $1.15T | A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis PainNCT07641517Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) | Phase 2 | Recruiting | Drug: LY4065967, Placebo | Osteoarthritis, Knee, Chronic Pain | 150 | 2026-06-25 | Apr 2027 | ≤ 254 d | 2026-08-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Food Effect on Tersolisib (LY4064809) in Healthy ParticipantsNCT07662798Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tersolisib | Phase 1 | Active, not recruiting | Drug: Tersolisib · Other: High-fat Meal, Low-fat Meal | Healthy | 60 | 2026-07-01 | Sep 2026 | ≤ 42 d | 2026-08-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336Change from Baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Not yet recruiting | Drug: Orforglipron, Dulaglutide | Diabetes Mellitus, Type 2 | 170 | Sep 2026 | Mar 2030 | ≤ 1,320 d | 2026-08-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Catalyst calendar · What changed · Readouts by condition · Search and filter the whole pipeline